NCT06447207Active, not recruiting
Occupational Therapy Led Social Prescription for People With Parkinson Disease
Social Prescription for Loneliness in Community-based Group Exercise Classes for People With Parkinson Disease
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
Loneliness is an epidemic that the U.S. Surgeon General implored must be addressed by society as a whole. Increased loneliness (i.e., distressing feelings of isolation) in people with Parkinson's disease (PD) has a pervasive impact and is associated with worsened motor and non-motor symptoms, and quality of life. The investigators expect that individuals participating socially in the community would experience less loneliness. However, for individuals with PD participating in community-based group exercise programs, the investigators have found that over one third still report being lonely. Therefore, an evidence-based program needs to be added to address a significant problem of loneliness for people with PD-and occupational therapy is the leading discipline to add the intervention because social participation is one of eight occupations that an occupational therapist is focused on optimizing. The chief executive officer at the Parkinson Association of the Rockies (PAR), members of the Colorado State University Occupational Therapy Department, and members of the University of Colorado's Parkinson's Exercise Research Consortium have teamed up to address pervasive loneliness. Social prescription is a prime evidence-based intervention to add to existing PD community-based exercise classes because it has been shown to reduce loneliness. For this project, the investigators detect participants in the 'lonely' range through a standardized assessment. The investigators will work with PAR staff who will refer individuals identifying as 'lonely' to an occupational therapist, who will complete an individualized occupational profile and write the appropriate social prescription from 11 different interventions (examples include: intergenerational intervention, animal companions, physical activity, occupational therapy) from established community resources recommended for social prescription. The proposed project is designed with three primary goals: (1) determine the reach of the social prescription program, (2) evaluate the effectiveness of the program at one site, and (3) determine implementation strategies for scalability.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 21 May 2024
- Start date
- 13 Aug 2024
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Colorado State University
- Diseases
- Parkinson disease
- NCT number
- NCT06447207
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 13 Aug 2024 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have ever been diagnosed with dementia
Other
- Not fluent in English
Who the study is looking for
- At least 18 years old
- Have a diagnosis of Parkinson Disease
- Have participated in at least one exercise class or support group in the last year
- Scored ≥5/9 on the UCLA 3-item Loneliness Scale during pre-screening
- Agree to participate in a 6-month program including a social prescription and six visits with an occupational therapist or occupational therapy doctoral student
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Colorado State University Coordinator of this site? Confirm its status | Fort Collins | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.